^
    Back
    Association details:
    Biomarker:IFNG gene signature overexpression
    Cancer:Melanoma
    Drug:Yervoy (ipilimumab) (CTLA4 inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: B - Late Trials
    Source:
    ESMO 2019
    Title:

    Adjuvant nivolumab (NIVO) versus ipilimumab (IPI) in resected stage III/IV melanoma: 3-year efficacy and biomarker results from the phase III CheckMate 238 trial

    Published date:
    09/28/2019
    Excerpt:
    High levels of all biomarkers analyzed (interferon-gamma gene expression signature, tumor mutational burden, and CD8+ T-cell infiltration by immunohistochemistry) showed an association with improved RFS for both NIVO and IPI.
    Trial ID:
    CheckMate 238